Skip Nav Destination
Issues
1 October 2001
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Editorials
Review
Minireview
Advances in Brief
Molecular Oncology, Markers, Clinical Correlates
Correlation of p53 Mutations with Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian Cancer1
Angela Reles; Wen H. Wen; Annette Schmider; Conway Gee; Ingo B. Runnebaum; Uta Kilian; Lovell A. Jones; Adel El-Naggar; Carmen Minguillon; Ines Schönborn; Olaf Reich; Rolf Kreienberg; Werner Lichtenegger; Michael F. Press
Experimental Therapeutics, Preclinical Pharmacology
Regular Articles
Clinical Trials
Phase I Trial of a Melanoma Vaccine with gp100280–288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes1
Craig L. Slingluff, Jr.; Galina Yamshchikov; Patrice Neese; Holly Galavotti; Shannon Eastham; Victor H. Engelhard; Dave Kittlesen; Donna Deacon; Sarah Hibbitts; William W. Grosh; Gina Petroni; Roger Cohen; Catie Wiernasz; James W. Patterson; Brian P. Conway; William G. Ross
A Phase I Trial and Pharmacokinetic Study of 9-cis-Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study1
Peter C. Adamson; Brigitte C. Widemann; Gregory H. Reaman; Nita L. Seibel; Robert F. Murphy; Andrea F. Gillespie; Frank M. Balis
Lack of Correlation of Functional Scintigraphy with 99mTechnetium-Methoxyisobutylisonitrile with Histological Necrosis following Induction Chemotherapy or Measures of P-Glycoprotein Expression in High-Grade Osteosarcoma1
Richard Gorlick; Alfred C. Liao; Cristina Antonescu; Andrew G. Huvos; John H. Healey; Rebecca Sowers; Mariza Daras; Elizabeth Calleja; Leonard H. Wexler; David Panicek; Paul A. Meyers; Samuel D. Yeh; Steven M. Larson
Cancer Biology, Immunology, Cytokines
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Cyclin D1 and p16 Alterations in Advanced Premalignant Lesions of the Upper Aerodigestive Tract: Role in Response to Chemoprevention and Cancer Development1
Vassiliki A. Papadimitrakopoulou; Julie Izzo; Li Mao; Jamie Keck; David Hamilton; Dong Moon Shin; Adel El-Naggar; Petra den Hollander; Diane Liu; Walter N. Hittelman; Waun K. Hong
Mutational Analysis of BRCA1 and BRCA2 and Clinicopathologic Analysis of Ovarian Cancer in 82 Ovarian Cancer Families: Two Common Founder Mutations of BRCA1 in Japanese Population1
Masayuki Sekine; Hiroshi Nagata; Shoji Tsuji; Yasuo Hirai; Seiichiro Fujimoto; Masayuki Hatae; Iwao Kobayashi; Tsuneo Fujii; Ichiro Nagata; Kimio Ushijima; Koshiro Obata; Mitsuaki Suzuki; Mitsuhiro Yoshinaga; Naohiko Umesaki; Shinji Satoh; Takayuki Enomoto; Satoru Motoyama; Kenichi Tanaka; The Japanese Familial Ovarian Cancer Study Group
Experimental Therapeutics, Preclinical Pharmacology
A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats
Lee M. Greenberger; Tami Annable; Karen I. Collins; Barry S. Komm; C. Richard Lyttle; Chris P. Miller; Pondichery G. Satyaswaroop; Yixian Zhang; Philip Frost
Expression of Her-2/neu in Human Lung Cancer Cell Lines by Immunohistochemistry and Fluorescence in Situ Hybridization and its Relationship to in Vitro Cytotoxicity by Trastuzumab and Chemotherapeutic Agents1
Paul A. Bunn, Jr.; Barbara Helfrich; Ariel F. Soriano; Wilbur A. Franklin; Marileila Varella-Garcia; Fred R. Hirsch; Anna Baron; Chan Zeng; Daniel C. Chan
Tumor Uptake and Elimination of 2′,2′-Difluoro-2′-deoxycytidine (Gemcitabine) after Deoxycytidine Kinase Gene Transfer: Correlation with in Vivo Tumor Response1
A. William Blackstock; Harry Lightfoot; L. Doug Case; Joel E. Tepper; Suresh K. Mukherji; Beverly S. Mitchell; Steve G. Swarts; Suzanne M. Hess
Letters to the Editor
Correspondence re: E. Sabo et al., Microscopic Analysis and Significance of Vascular Architectural Complexity in Renal Cell Carcinoma. Clin. Cancer Res., 7: 533–537, 2001.
Fabio Grizzi; Piergiuseppe Colombo; Barbara Barbieri; Barbara Franceschini; Massimo Roncalli; Maurizio Chiriva-Internati; Pier Carlo Muzzio; Nicola Dioguardi; Fondazione
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.